2Seventy Bio

2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its workforce. The company also plans to expand its collaboration with JW Therapeutics.

2seventy bio (TSVT) to Cut Jobs & Expand JW Therapeutics Deal

2seventy bio said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma.

2seventy bio to lay off 40% of workforce

2seventy bio Inc. stock TSVT, -6.81% rose 2.7% in premarket trading on Tuesday after the T-cell drug company for cancer treatment said it's cutting 176 jobs or 40% of its work force and launching a search for a new chief executive. Current chief executive Nick Leschly will become chairman of the company's board.

2seventy bio cutting 176 jobs, search for new chief executive

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a restructuring of its business operations and research and development model to significantly reduce costs while supporting the execution of a prioritized plan for the long-term growth of the company. “2seventy's mission remains the same: to unleash the power of the T-cell and develop un-incremental treatments for people living with cancer,” said Nick Leschly, chief kairos officer. “However, the macro environ.

2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway

CAMBRIDGE, Mass. & SHANGHAI, China--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, and JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, today announced their intention to expand their strategic alliance. The expansion, based on the partnership that was established last year, builds upon the companies' translational and clini.

2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, announced today that members of the management team will participate in a fireside chat at the upcoming 2023 Morgan Stanley Global Healthcare Conference on September 13, 2023 at 3:35pm ET in New York. A live webcast will be available via the Investors and Media section of 2seventy bio's website at https://ir.2seventybio.com/. A replay will be archived on 2seventy bio's site for.

2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference

2seventy bio, Inc. (NASDAQ:TSVT ) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Jenn Snyder - SVP of Corporate Affairs Nick Leschly - President and Chief Executive Officer Philip Gregory - Chief Scientific Officer Steven Bernstein - Chief Medical Officer William Baird - Chief Financial Officer Conference Call Participants Daina Graybosch - Leerink Partners Yaron Werber - TD Cowen Kelsey Goodwin - Guggenheim Vikram Purohit - Morgan Stanley Daina Graybosch - Leerink Partners John Newman - Canaccord Genuity Operator Good day and thank you for standing by. Welcome to the 2seventy bio Second Quarter 2023 Earnings Conference Call.

2seventy bio, Inc. (TSVT) Q2 2023 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the second quarter ended June 30, 2023. “We launched 2seventy in late 2021 with the stated mission of delivering more time for people living with cancer through the transformative power of cell therapy,” said Nick Leschly, chief kairos officer. Since the creation of 2seventy, our mission has always been dual-pronged: to.

2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its second quarter 2023 financial results on Monday, August 14, 2023. 2seventy bio will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide a business update. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com/.

2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, announced today that members of the management team will present at the upcoming 2023 Wedbush PacGrow Healthcare Conference on August 8, 2023 at 8:00am ET in New York. About 2seventy bio Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour –.

2seventy bio to Participate in 2023 Wedbush PacGrow Healthcare Conference

2seventy bio: Nothing Properly Explains The Low Valuation

Following a patient's death, investigators pause an early-stage study on 2seventy bio's (TSVT) CAR-T cell therapy in AML indication. However, it is still unclear whether the death was due to the treatment.

2seventy (TSVT) Down 9% on Patient Death in Leukemia Study

Seattle Children's Therapeutics paused a study of 2seventy Bio's AML treatment after a patient died. TSVT stock crumbled on the news.

2seventy Bio Stock Crumbles After A Patient Dies In Its Pediatric Cancer Study

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that the Phase 1 trial of the PLAT-08 study of SC-DARIC33 in Acute Myeloid Leukemia (AML) has been paused by Seattle Children's, the Company's partner and the regulatory sponsor of the study. The pause was instituted as part of the clinical study protocol stopping rules in response to a recent Grade 5 (fatal) serious adverse event (SAE) and was followed by the re.

2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that members of the management team will participate in a fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 6:20pm ET in Dana Point, CA. A live webcast will be available via the Investors and Media section of 2seventy bio's website at https://ir.2seventybio.com/. A replay will be archived on 2seven.

2seventy bio to Participate in Upcoming Investor Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced late-breaking results from the ongoing Phase 1 PLAT-08 trial, in collaboration with Seattle Children's Therapeutics, evaluating SC-DARIC33 in relapsed or refractory pediatric and young adult AML patients, as well as an oral presentation evaluating regulated IL-15 production combined with DARIC33 activation for anti-AML potency. The data were presented at this yea.

2seventy bio Presents Late-Breaking Results for SC-DARIC33, an Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced new data featuring novel approaches combining the company's platform CAR T cell and T cell receptor technology and unique cell therapy engineering capabilities to potentially enhance treatment potency in a range of cancers. The data were shared in three presentations at this year's American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Los Angeles,.

2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) today announced the presentation of four abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 2-6, 2023 in Chicago, Illinois and six abstracts at the European Hematology Association (EHA) Congress, taking place in Frankfurt, Germany from June 8-11, 2023. The presentations will highlight clinical and correlative data from the KarMMa-2 and KarMMa-3 clinical trials evaluating Abecma.

2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023

2seventy bio, Inc. (NASDAQ:TSVT ) Q1 2023 Earnings Call Transcript May 3, 2023 4:30 PM ET Company Participants Jenn Snyder - SVP of Corporate Affairs Nick Leschly - President, CEO & Director Philip Gregory - Chief Scientific Officer Steven Bernstein - Chief Medical Officer William Baird - CFO Conference Call Participants Daina Graybosch - SVB Securities LLC Operator Good day, and thank you for standing by. Welcome to the 2seventy bio First Quarter 2023 Financial Results Conference Call.

2seventy bio, Inc. (TSVT) Q1 2023 Earnings Call Transcript

2seventy bio, Inc. (TSVT) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to loss of $3.20 per share a year ago.

2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy Company, today reported financial results and recent highlights for the first quarter ended March 31, 2023. “We are off to a strong start in 2023, with a sharp focus on timely execution across our commercial business, clinical programs, and research pipeline,” said Nick Leschly, chief kairos officer, 2seventy bio. “Abecma revenue remains on a strong growth trajectory as we continue to su.

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced the presentation of five abstracts, including one late-breaking oral presentation, at this year's American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, California from May 16-20, 2023. The late-breaking abstract featuring early findings from the ongoing Phase 1 PLAT-08 trial in collaboration with Seattle Children's Thera.

2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) a leading immuno-oncology cell therapy company, today announced that it has achieved a preclinical $15 million milestone as part of the joint research and development collaboration focused on an in vivo gene editing treatment for hemophilia A. The milestone is a result of delivering key pre-clinical proof of concept data that the Company plans to present during a virtual Research and Development deep dive on May 19, 2023. “Hem.

2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, will announce its first quarter 2023 financial results on Wednesday, May 3, 2023. 2seventy bio will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. Participants can access the conference call live via webcast which will be available on the investor page of the company's website at https://ir.2seventybio.com/. Participants.

2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023

Martinsried /M unich , March 29 , 2023 . Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the year ended December 31, 2022 and provided a corporate update.

News for 2Seventy Bio Stock (TSVT)